Premium
S4–04–02: M1 muscarinic agonists as a comprehensive therapy in Alzheimer's disease
Author(s) -
Fisher Abraham,
Caccamo Antonela,
Oddo Salvatore,
Billings Lauren M.,
Green Kim N.,
Brandeis Rachel,
Pittel Zippora,
Barner Nira,
Elkon Hanoch,
Laferla Frank M.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.285
Subject(s) - muscarinic acetylcholine receptor , hyperphosphorylation , hippocampus , cholinergic , muscarinic acetylcholine receptor m4 , neuroscience , muscarinic acetylcholine receptor m1 , medicine , endocrinology , psychology , biology , receptor , kinase , microbiology and biotechnology
contextual memory was also measured. Conclusions: We have identified a number of development candidates aimed at targeting either improved symptomatic therapy or disease slowing. This ‘multiple shots on goal’ approach using multiple platforms and multiple targets will help to increase the likelihood of delivering novel therapeutics to patients. Ultimately, the success of our programs, will be judged by our ability to deliver novel therapies to patients with significant positive impact on their lives, and a slowing, halting or perhaps even reversing of this devastating disease process.